TARAHIGH SIGNALFINANCIAL10-K

TARA experienced a dramatic 69.5% decline in cash reserves from $162.8M to $49.7M while operating losses deepened significantly and share count increased by 47%.

The massive cash burn combined with worsening operating losses (-$35.8M to -$56.4M operating cash flow) raises immediate liquidity concerns for this biotech company. The 47% increase in outstanding shares (36.8M to 54.1M) suggests substantial dilutive equity raises were needed to fund operations, which explains how stockholders' equity increased despite mounting losses.

Comparing 2026-03-10 vs 2025-03-05View on EDGAR →
FINANCIAL ANALYSIS

TARA's financial position deteriorated markedly with cash declining 69.5% to $49.7M while operating losses expanded across all metrics - R&D expenses surged 34.5%, operating losses widened 31.3% to -$64.5M, and operating cash outflow increased 57.4% to -$56.4M. Despite growing total assets 15.4% and stockholders' equity 17.5%, the 47% share count increase indicates significant dilutive financing was required. The combination of accelerating cash burn, deepening losses, and substantial shareholder dilution signals mounting financial stress for investors.

FINANCIAL STATEMENT CHANGES
Cash & Equivalents
Balance Sheet
-69.5%
$162.8M→$49.7M

Cash declined 69.5% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Operating Cash Flow
Cash Flow
-57.4%
-$35.8M→-$56.4M

Operating cash flow fell 57.4% — earnings quality concerns; investigate working capital changes and non-cash items.

Capital Expenditure
Cash Flow
+49.2%
$63K→$94K

Capital expenditure jumped 49.2% — major investment cycle underway; assess returns on deployment.

R&D Expense
P&L
+34.5%
$31.7M→$42.6M

R&D investment increased 34.5% — signals commitment to future product development, though near-term margin impact.

Operating Income
P&L
-31.3%
-$49.2M→-$64.5M

Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.

Net Income
P&L
-28.8%
-$44.6M→-$57.4M

Net income declined 28.8% — review whether driven by operations, interest costs, or non-recurring items.

Stockholders Equity
Balance Sheet
+17.5%
$167.1M→$196.4M

Equity base grew 17.5% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Total Assets
Balance Sheet
+15.4%
$181.5M→$209.5M

Asset base grew 15.4% — expansion through organic growth, acquisitions, or capital deployment.

LANGUAGE CHANGES
NEW — 2026-03-10
PRIOR — 2025-03-05
ADDED
As of March 5, 2026, 54,084,378 shares of the registrant s common stock, $0.001 par value, were outstanding.
Forward-looking statements include all statements other than statements of historical facts, including statements regarding our business, operations and financial performance and conditions, as well as our plans, objectives and expectations for our business operations and financial performance and condition.
Forward-looking statements inherently involve many risks and uncertainties that could cause actual results to differ from those expressed in forward-looking statements.
However, we can give no assurance that any expectation or belief will result or will be achieved or accomplished.
Investors therefore should not place undue reliance on forward-looking statements.
Investors should also carefully read the factors described under Item 1A.
Risk Factors in this Annual Report on Form 10-K for a description of certain risks that could, among other things, cause our actual results to differ from those expressed in forward-looking statements.
Investors should understand that it is not possible to predict or identify all such factors and should not consider the risks described above and under Item 1A.
Risk Factors to be a complete statement of all potential risks and uncertainties.
Additional discussion of the risks and uncertainties summarized in this risk factor summary, and other risks and uncertainties that we face, are set forth in Part I, Item 1A.
REMOVED
As of February 28, 2025, 36,767,465 shares of the registrant s common stock, $0.001 par value, were outstanding.
Statements, other than statements of historical facts, contained in this document, including statements regarding our business, operations and financial performance and conditions, as well as our plans, objectives and expectations for our business operations and financial performance and condition, are forward-looking statements.
We caution readers not to place undue reliance on forward-looking statements.
Additional discussion of the risks and uncertainties summarized in this risk factor summary, and other risks and uncertainties that we face, are set forth in Part I, Item 1A, Risk Factors, and should be carefully considered, together with other information in this Annual Report on Form 10-K and our other filings with the SEC before making investment decisions regarding our securities.
Disruptions at the FDA or other comparable foreign regulatory authorities may also slow the time necessary for new products to be reviewed and/or approved, which would adversely affect our business.
In addition, there is substantial uncertainty regarding the new U.S.
We are subject to stringent and changing obligations related to data privacy and security.
TARA-002 is currently approved in Japan and Taiwan for lymphatic malformations, or LMs, and multiple oncologic indications.
Bladder cancer is the sixth most common cancer in the United States, with NMIBC representing approximately 80% of bladder cancer diagnoses.
Approximately 65,000 patients are diagnosed with NMIBC in the United States each year.
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →